Telomir Pharmaceuticals向FDA提交Telomir-1 (Telomir-Zn)用于治疗晚期及转移性三阴性乳腺癌的新药临床试验申请

美股速递03-31

Telomir Pharmaceuticals已正式向美国食品药品监督管理局提交了其候选药物Telomir-1（亦称为Telomir-Zn）的新药临床试验申请。该申请旨在评估该药物在治疗晚期及转移性三阴性乳腺癌患者中的潜力。这一进展标志着公司在推进其创新疗法方面迈出了关键一步。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1147882713?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-31 19:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147882713","market":"us","top_or_hot":-1,"title":"Telomir Pharmaceuticals向FDA提交Telomir-1 (Telomir-Zn)用于治疗晚期及转移性三阴性乳腺癌的新药临床试验申请","media":"美股速递","content":"<p>Telomir Pharmaceuticals已正式向美国食品药品监督管理局提交了其候选药物Telomir-1（亦称为Telomir-Zn）的新药临床试验申请。该申请旨在评估该药物在治疗晚期及转移性三阴性乳腺癌患者中的潜力。这一进展标志着公司在推进其创新疗法方面迈出了关键一步。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telomir Pharmaceuticals向FDA提交Telomir-1 (Telomir-Zn)用于治疗晚期及转移性三阴性乳腺癌的新药临床试验申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelomir Pharmaceuticals向FDA提交Telomir-1 (Telomir-Zn)用于治疗晚期及转移性三阴性乳腺癌的新药临床试验申请\n</h2>\n\n<h4 class=\"meta\">\n\n2026-03-31 19:09 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Telomir Pharmaceuticals已正式向美国食品药品监督管理局提交了其候选药物Telomir-1（亦称为Telomir-Zn）的新药临床试验申请。该申请旨在评估该药物在治疗晚期及转移性三阴性乳腺癌患者中的潜力。这一进展标志着公司在推进其创新疗法方面迈出了关键一步。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1147882713","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147882713","pubTimestamp":1774955356,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Telomir Pharmaceuticals已正式向美国食品药品监督管理局提交了其候选药物Telomir-1（亦称为Telomir-Zn）的新药临床试验申请。该申请旨在评估该药物在治疗晚期及转移性三阴性乳腺癌患者中的潜力。这一进展标志着公司在推进其创新疗法方面迈出了关键一步。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","TELO":"Telomir Pharmaceuticals"},"translate_title":"Telomir Pharmaceuticals submits a new drug clinical trial application to the FDA for Telomir-1 (Telomir-Zn) for the treatment of advanced and metastatic triple-negative breast cancer","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TELO":1},"content_text":"Telomir Pharmaceuticals已正式向美国食品药品监督管理局提交了其候选药物Telomir-1（亦称为Telomir-Zn）的新药临床试验申请。该申请旨在评估该药物在治疗晚期及转移性三阴性乳腺癌患者中的潜力。这一进展标志着公司在推进其创新疗法方面迈出了关键一步。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147882713","isCrawlerRequest":true}